ln this proposal we outline plans to investigate the immunopathogenesis of acute and early HIV-1 infection using sequential therapeutic interventions with antiretroviral chemotherapeutic agents and therapeutic vaccination in an attempt to manipulate the virus-host interaction to the benefit of the host. Our group consists of clinical sites in the United States (Denver arid Atlanta), Brazil and Zimbabwe and an interactive group of laboratory investigators based at the Universities of Colorado and Minnesota and at Rush Medical School. We plan to enroll 30 acutely infected and 90 patients with early HIV infection into an integrated program of randomized clinical trials that will feature early initiation of potent chemotherapeutic combination antiretroviral regimens designed to maximize tolerability, convenience and adherence and to minimize toxicity. Study participants achieving undetectable levels of plasma HIV-1 RNA will be offered entry into controlled clinical trials of therapeutic vaccination using several different vaccine approaches designed to maximize virus specific cellular immunity .The impact of therapeutic interventions will be evaluated by the extent to which viral replication is controlled by host effector mechanisms following therapeutic interruption. The immunopathogenesis of acute HIV-1 infection will be intensively evaluated in the context of these sequential therapeutic interventions by a coordinated series of laboratory studies that will evaluate the role of cellular and humoral HIV-1 specific effector mechanisms and soluble mediators in controlling HIV-1 expression in plasma and lymphoid tissues and in facilitating immune reconstitution following establishment of control of viral replication. Studies of the role of viral fitness and diversity will also be undertaken. The goals of these investigations are to better understand virus-host interactions in the context of acute HIV-1 infection, to improve therapeutic approaches to HIV-1 infection and to provide insights that will prove useful in AIDS vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI055356-01
Application #
6656106
Study Section
Special Emphasis Panel (ZAI1-VSG-A (J1))
Program Officer
Reese, Karen B
Project Start
2003-09-30
Project End
2008-03-31
Budget Start
2003-09-30
Budget End
2004-03-31
Support Year
1
Fiscal Year
2003
Total Cost
$1,035,733
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
McGinty, Tara; Mirmonsef, Paria; Mallon, Patrick W G et al. (2016) Does systemic inflammation and immune activation contribute to fracture risk in HIV? Curr Opin HIV AIDS 11:253-60
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Rowan, Sarah E; Burman, William J; Johnson, Steven C et al. (2014) Engagement-in-care during the first 5 years after HIV diagnosis: data from a cohort of newly HIV-diagnosed individuals in a large US city. AIDS Patient Care STDS 28:475-82
Meditz, Amie L; Connick, Elizabeth; McCarter, Martin (2014) Safety of excisional inguinal lymph node biopsies performed for research purposes in HIV-1-infected women and men. Surg Infect (Larchmt) 15:399-403
Gardner, Edward M; Daniloff, Elaine; Thrun, Mark W et al. (2013) Initial linkage and subsequent retention in HIV care for a newly diagnosed HIV-infected cohort in Denver, Colorado. J Int Assoc Provid AIDS Care 12:384-90
Hogan, Christine M; Degruttola, Victor; Sun, Xin et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205:87-96
Dillon, Stephanie M; Friedlander, Laura J; Rogers, Lisa M et al. (2011) Blood myeloid dendritic cells from HIV-1-infected individuals display a proapoptotic profile characterized by decreased Bcl-2 levels and by caspase-3+ frequencies that are associated with levels of plasma viremia and T cell activation in an exploratory st J Virol 85:397-409
Meditz, Amie L; MaWhinney, Samantha; Allshouse, Amanda et al. (2011) Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 203:442-51
Miura, Toshiyuki; Brumme, Zabrina L; Brockman, Mark A et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 84:7581-91
Howe, Rawleigh; Dillon, Stephanie; Rogers, Lisa et al. (2009) Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. J Acquir Immune Defic Syndr 50:444-56

Showing the most recent 10 out of 20 publications